The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is
Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry…
The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four holdings, combining for 25.96% of net assets. With HDV up 19.66% year-to-date and yielding roughly 3%, I want to know whether the checks these four giants send to BlackRock are actually safe.
At $4.08 per share against $5.85 in trailing 12-month EPS, Exxon runs a 69.74% earnings payout ratio. Fiscal year 2025 free cash flow of $26.13 billion easily covered the dividend, and interest coverage of 56.28x is extraordinary by any measure. CEO Darren Woods highlighted “an industry-leading balance sheet that gives us unmatched flexibility.” Rating: Very Safe.
Chevron: Hess Cash Flow Reset the Math
After the Hess close, Chevron delivered $18.10 billion in free cash flow during the second quarter of 2026, representing a 272% increase, and the company reduced debt by $8.41 billion in the same quarter. Net Debt to EBITDA sits at 1.08x, with interest coverage of 13.70x. CEO Mike Wirth flagged that the “$3 billion in annual run-rate savings” target was hit six months ahead of schedule. The payout ratio is elevated at $6.98 on $10.18 in earnings, though cash flows comfortably cover it. Rating: Safe.
Johnson & Johnson: The Dividend King Earns Its Crown
With an earnings payout ratio of 60.16% on $8.71 EPS, JNJ leaves itself a real cushion. Fiscal year 2025 free cash flow of $19.70 billion and raised 2026 guidance of $11.45 to $11.65 adjusted EPS underwrite the payout, even with first-quarter litigation charges in the mix. CEO Joaquin Duato called 2026 “a year of accelerated growth and impact.” An AAA credit rating and 64 consecutive dividend raises seal the case. Rating: Very Safe.
AbbVie: Growing but Leveraged
At $6.83 annually, ABBV yields 2.80%. The trailing P/E of 69 overstates the strain, since the forward P/E is 18, though Net Debt to EBITDA of 2.26x and negative book equity from the Allergan deal keep me cautious. Skyrizi and Rinvoq brought in a combined $8.04 billion in the second quarter of 2026, and they are replacing Humira faster than expected. Rating: Safe with a watchlist tag.
The Verdict on HDV’s Income Engine
Three of the four checks that fund HDV are rock solid. The income profile looks durable as long as crude stays above the EIA’s $79/b 2027 forecast and AbbVie’s immunology handoff holds together. The setup starts to weaken if oil retraces sharply and ABBV’s leverage bites at the same time.
David Beren has been a Flywheel Publishing contributor since 2022. Writing for 24/7 Wall St. since 2023, David loves to write about topics of all shapes and sizes. As a technology expert, David focuses heavily on consumer electronics brands, automobiles, and general technology. He has previously written for LifeWire, formerly About.com. As a part-time freelance writer, David’s “day job” has been working on and leading social media for multiple Fortune 100 brands. David loves the flexibility of this field and its ability to reach customers exactly where they like to spend their time. Additionally, David previously published his own blog, TmoNews.com, which reached 3 million readers in its first year. In addition to freelance and social media work, David loves to spend time with his family and children and relive the glory days of video game consoles by playing any retro game console he can get his hands on.
Chevron (NYSE:CVX | CVX Price Prediction) is an integrated energy major whose July 2025 Hess acquisition added Guyana, Bakken, and Gulf of America assets. With WTI near $95 and the Fed funds rate sitting…
With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.
The Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) is one of the simplest income vehicles in the market: it owns roughly 500 U.S. stocks that pay above-average dividends, weights them by market…
Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through…
ExxonMobil (NYSE: XOM | XOM Price Prediction) and Chevron (NYSE: CVX) both reported Q1 2026 earnings on May 1, 2026, and the earnings reports arrived in the middle of a volatile oil market. WTI…
Three blue-chip dividend stocks, each on a different quarterly payment schedule, can fill every month of the year with income, but each one carries a distinct risk that could derail the whole ladder.
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus…
Energy stocks just gave investors a buying window. After WTI crude spiked to $114.58 per barrel on April 7, on the Strait of Hormuz disruption, prices have cooled to $78.94 per barrel as of…
At $160.49, ExxonMobil (NYSE:XOM | XOM Price Prediction) is a buy and at $196.12, Chevron (NYSE:CVX) is a hold. The two integrated majors have both ripped higher in 2026 on stronger production, capital discipline,…